Novo Nordisk's Etavopivat Achieves Positive Phase 3 Results in Sickle Cell Disease Trial

on

Novo Nordisk announced positive topline results from the Phase 3 HIBISCUS trial for etavopivat on April 20, 2026.

Etavopivat met both co-primary endpoints in patients with sickle cell disease.1

The trial evaluated etavopivat's efficacy in reducing vaso-occlusive crises.13

Earlier Phase 2 HIBISCUS data showed reductions in vaso-occlusive crises incidence through 52 weeks.3

Sources:

1. https://www.marketscreener.com/news/novo-nordisk-reports-positive-phase-3-results-for-etavopivat-in-sickle-cell-disease-ce7e50d3d08bf522

3. https://www.prnewswire.com/news-releases/novo-nordisk-to-present-new-data-highlighting-innovative-rare-blood-disorders-pipeline-at-ash-2024-302320903.html